JHP Pharmaceuticals, located in Parsippany, New Jersey, is an integrated
specialty healthcare company that specializes in sterile injectable
products. JHP manufactures and sells brand aseptic injectable
pharmaceuticals in hospital and clinical settings and provides contract
manufacturing services for global pharmaceutical companies. JHP's own
product portfolio includes leading diagnostic, women's health and
anesthesia products. All products have a long track record of "gold
standard" service and are at or near the front line of treatment in
their therapeutic indications. Contract manufactured products include
some of the leading global biologic products which involve liquid,
lyophilized and suspension presentations.
Par Pharmaceutical Statement on Brevital® Sodium
Par Pharmaceutical Companies, Inc. today issued the following statement in response
to inquiries it has received regarding the potential use of Brevital® Sodium
(methohexital sodium for injection, USP) by the State of Indiana Department of Correction
as part of a three-drug lethal injection protocol: Brevital® is a medically important
anesthetic that physicians and hospital pharmacies have relied upon for more than 50 years.
Par Pharmaceutical to Acquire JHP Pharmaceuticals
Par Pharmaceutical Companies, Inc. (“Par”) today announced that it
has entered into a definitive agreement to acquire JHP Group Holdings, the parent
company of JHP Pharmaceuticals (“JHP”), a leading specialty pharmaceutical
company that develops, manufactures and markets branded and generic sterile injectable products.